ImmunityBio, Inc. (NASDAQ:IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.
IBRX Reports 700% Revenue Surge in 2025
ImmunityBio announced preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a remarkable 700% increase year-over-year.
Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ (CIS).
For the fourth quarter of 2025, the company reported revenue of about $38.3 million, surpassing the previous quarter’s $31.8 million, marking a 20% quarter-over-quarter increase and a 431% year-over-year increase.
The company highlighted a 750% increase in unit sales volume for its product Anktiva in 2025 compared to 2024.
“We delivered strong quarter-over-quarter revenue growth, …
Leave a Reply
You must be logged in to post a comment.